N-Acetyl Lenalidomide is a structurally modified derivative of Lenalidomide, featuring an acetyl group appended to the terminal amino functionality of the glutarimide core. This modification introduces an acetoamido substituent, altering the compound’s hydrophobic character while retaining the phthalimide pharmacophore. The acetylation occurs at the 5-position of the glutarimide ring, distinguishing it from the parent drug’s primary amine. Synthetically, this impurity arises during API manufacturing via acetylating agent carryover. It serves as a critical HPLC reference standard for quantifying process-related acetylated impurities in Lenalidomide formulations.
On Request| Std | Catalog # | Quantity | Price |
|---|---|---|---|
| USP | 1A03660 ↗ | 25 mg | — |
CC(=O)NC1=CC=CC2=C1CN(C2=O)C3CCC(=O)NC3=O
InChI=1S/C15H15N3O4/c1-8(19)16-11-4-2-3-9-10(11)7-18(15(9)22)12-5-6-13(20)17-14(12)21/h2-4,12H,5-7H2,1H3,(H,16,19)(H,17,20,21)
IUJSAVPLRWRWOF-UHFFFAOYSA-N